The Safety and Effectiveness of Taneasy and Actein in COPD Patients
Status:
COMPLETED
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of Taneasy 600mg granules and Actein effervescent tablets 600MG administered twice daily for 14 days in treatment of COPD Disease.
Phase:
PHASE4
Details
Lead Sponsor:
Bun Yao Biotechnology Co., Ltd
Collaborators:
KGS Pharmamate Co., Ltd Taichung Veterans General Hospital, Taichung